2852-LB: Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Icodec in People with Type 2 Diabetes (PWT2D): A Systematic Literature Review and Network Meta-analysis
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2852-lb ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von ROBERT RITZEL und 9 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction and Objective: No head-to-head studies compare daily Gla-300 vs weekly insulin Icodec. This analysis compared these two basal insulins in insulin-naïve PWT2D on OADs.
Methods
MEDLINE®, Embase, and CENTRAL databases were searched on July 3, 2025 for RCTs evaluating once-daily Gla-300 or once-weekly Icodec in insulin-naïve PWT2D. Treatment effects at ~6 months were estimated using Bayesian and frequentist models.
Results
Five RCTs (n=3,246; Gla-300 n=2,411; Icodec n=835) with comparable baseline characteristics were included (Table). Gla-300 was consistently associated with lower risk and event rates of 24-hour hypoglycemia vs Icodec, including level 1, level 2, and combined level 2/3 hypoglycemia. No significant differences were observed for level 3 hypoglycemia. Glycemic outcomes were generally similar, with no significant differences in HbA1c or body weight change. Gla-300 patients were less likely to attain HbA1c <7%, and FPG reduction was smaller vs Icodec; final daily insulin dose (U/day) was higher, with no difference per U/kg. Non-hypoglycemia safety outcomes were comparable. Frequentist analyses were broadly concordant (data not shown).
Conclusion
In insulin-naïve PWT2D on OADs, Gla-300 was associated with lower level 1 and 2 hypoglycemia risk vs Icodec, with broadly comparable glycemic measures and overall safety at ~6 months. Disclosure R. Ritzel: Other - Advisory board/speaker bureau/honoraria; Current; Novo Nordisk, Sanofi, Merck & Co., Inc., AstraZeneca, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc. F. Gomez-Peralta: Research Support; Ended; Abbott Diabetes, Novo Nordisk. Research Support; Current; Eli Lilly and Company. Speaker's Bureau; Ended; AstraZeneca. Advisory Panel; Current; Insulcloud SL, Sanofi. Speaker's Bureau; Ended; Sanofi. R. Napoli: None. A. Ratzki-Leewing: Advisory Panel; Current; Sanofi. Consultant; Current; Vertex Pharmaceuticals Incorporated, Dexcom, Inc. Research Support; Current; Sanofi. Other - Paid presentation; Ended; Abbott. Consultant; Current; Sanofi. M. N. Mabunay: Employee; Current; Sanofi. M. Szigeti: Employee; Current; Sanofi. S. Sanyal: Employee; Current; Sanofi. A. Alvarez: Employee; Current; Sanofi. V. Wan: Consultant; Current; Sanofi. F. Giorgino: Advisory Panel; Current; Abbott. Consultant; Current; Lilly, Novo Nordisk. Advisory Panel; Current; AstraZeneca, Medtronic. Research Support; Current; Roche Diabetes Care. Advisory Panel; Current; LifeScan, Sanofi. Advisory Panel; Ended; Merck Sharp & Dohme Corp. Advisory Panel; Current; Boehringer Ingelheim International GmbH. Funding This study was funded by Sanofi
Zitieren
APA
RITZEL, R., GOMEZ-PERALTA, F., NAPOLI, R., RATZKI-LEEWING, A., MABUNAY, M. A. N., SZIGETI, M., SANYAL, S., ALVAREZ, A., WAN, V., & GIORGINO, F. (2026). 2852-LB: Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Icodec in People with Type 2 Diabetes (PWT2D): A Systematic Literature Review and Network Meta-analysis. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2852-lb
Vancouver
RITZEL R, GOMEZ-PERALTA F, NAPOLI R, RATZKI-LEEWING A, MABUNAY MAN, SZIGETI M, et al. 2852-LB: Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Icodec in People with Type 2 Diabetes (PWT2D): A Systematic Literature Review and Network Meta-analysis. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2852-lb
BibTeX
@article{RITZEL2026,
author = {RITZEL, ROBERT and GOMEZ-PERALTA, FERNANDO and NAPOLI, RAFFAELE and RATZKI-LEEWING, ALEXANDRIA and MABUNAY, MARIA AILEEN N. and SZIGETI, MATYAS and SANYAL, SHREOSI and ALVAREZ, AGUSTINA and WAN, VICTORIA and GIORGINO, FRANCESCO},
title = {2852-LB: Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Icodec in People with Type 2 Diabetes (PWT2D): A Systematic Literature Review and Network Meta-analysis},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2852-lb}
}
EUVIMED